- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01613560
Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the decision-making process of a systemic adjuvant therapy for ER-positive/HER2-negative breast cancer, to avoid adjuvant chemotherapy is an attractive but hard choice. On one hand, the result of tamoxifen endocrine therapy combined with adjuvant chemotherapy is superior to tamoxifen endocrine therapy alone for ER-positive breast cancer patients; on the other hand, the benefit that adjuvant chemotherapy provides to breast cancer with high hormone receptor expression is not clear and the tolerance of chemotherapy is much lower than that of endocrinotherapy.
St. Galen consensus on adjuvant therapy for early breast cancer recommends adopting simple endocrinotherapy and avoiding adjuvant chemotherapy for medium- and low- risk breast cancer with hormone receptor highly expressed. However, the results of study P024 and IMPACT suggest that hormone receptor expression is insufficient to predict the effect of endocrinotherapy.
At present, the proven clinical value of neoadjuvant endocrinotherapy is to assist surgery. Consensus recommends neoadjuvant endocrinotherapy for the patients with postmenopausal breast cancer who plan to receive simple adjuvant endocrinotherapy. The current study results show that neoadjuvant endocrinotherapy may be used as an experimental treatment platform, i.e., it can predict the results of adjuvant endocrinotherapy through comprehensive analysis of multiple indexes of the surgery samples after neoadjuvant endocrinotherapy.
By using P024 and IMPACT samples, Ellis et al studied the relation between survival and the test results of surgery samples after neoadjuvant endocrinotherapy, and obtained PEPI (the preoperative endocrine prognostic index). They have preliminarily proved that the PEPI score is relative to RFS (relapse-free survival) of postmenopausal ER-positive breast cancer treated with simple endocrinotherapy and to BCSS (breast cancer-specific survival).
A retrospective study,performed by breast prevention and treatment center in Peking University Cancer Hospital,shows that RFS in PEPI score ≤ 1 group is superior to the PEPI > 1 group after 16 weeks of neoadjuvant endocrinotherapy(p = 0.037), and RFS in effective group (Miller&Payne G1G2G3) is better than that in ineffective group (p=0.001) in terms of pathological evaluation.
The objective of this study is to prospectively verify the relation of efficacy of neoadjuvant hormonal therapy, and preliminarily explore the clinical value of complementary adjuvant chemotherapy to predict poor prognosis malignant breast cancer after neoadjuvant endocrinotherapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Peking University First Hospital
-
Beijing, Beijing, China
- Beijing Hospital
-
Beijing, Beijing, China
- 307 Hospital of PLA
-
Beijing, Beijing, China, 100142
- Peking Cancer Hospital & Institute
-
Beijing, Beijing, China
- 301 Hospital of Pla
-
Beijing, Beijing, China
- Beijing Chao-Yang Hospital
-
Beijing, Beijing, China
- Cancer Institution and Hospital.Chinese Academy of Medical Sciences
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- The 2nd Affiliated Hospital of Harbin Medical University
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Cancer Hospital
-
-
Jilin
-
Changchun, Jilin, China
- the First Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, China
- The First Hospital of China Medical University
-
-
Shandong
-
Jinan, Shandong, China
- The Second Hospital of Shandong University
-
-
Shanghai
-
Shanghai, Shanghai, China
- Fudan University Shanghai Cancer Center
-
Shanghai, Shanghai, China
- Shanghai Ruijin Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Female, not more than 75 years old, judged to have been in menopause by the investigator when enrolled. Refer to the following criteria to determine whether they are postmenopausal breast cancer.
- Spontaneous amenorrhea for more than 12 months Age ≥ 60 Age < 60, but FSH and E2 reach postmenopausal level.
- Received bilateral ovariectomy previously
- Not to define the women using LHRH agonists or antagonists as in postmenopausal state.
- Evidence of primary invasive breast cancer is confirmed by histopathological diagnosis.
- Clinical stage is T2-3N0M0
- ER or PgR are expressed in more than 50 percent of tumour cells, and HER2 is negative.
- No abnormal axillary nodes in ultrasound examination; no evidence of cancer metastasis confirmed by abnormal lymph node puncture pathological examination
- With plan of receiving simple endocrinotherapy and avoiding adjuvant chemotherapy
- No previous breast cancer treatment history
- No other tumors previously; no unstable complications or uncontrolled infection.
- No contraindication for endocrinotherapy with 3rd generation of aromatase inhibitors
- Participate in the trial voluntarily and sign the informed consent form.
Exclusion Criteria:
- Evidence of distant breast cancer metastasis by pathological and imaging diagnosis
- Patients who have a history of other malignant tumors
- With contraindications for 3rd generation of aromatase inhibitors
- Physical condition can not bear the experiment
- Patients who have potential mental, psychological, familial, social, geographic, or other factors that can hinder study regime performance.
- Patients who were treated or are treated with other anti-tumor measures before or during this trial, or planed to participate in other clinical trials.
- Patients who refuse to participate in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PEPI:2-4 group-A
|
preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
|
ACTIVE_COMPARATOR: PEPI:2-4 group-B
|
preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
|
ACTIVE_COMPARATOR: PEPI:0-1group
|
preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RFS
Time Frame: after a follow up of 5 years
|
RFS events includes local recurrence, regional recurrence, and distant metastasis resulted from breast cancer
|
after a follow up of 5 years
|
DDFS
Time Frame: after a follow up of 5 years
|
DDFS events includes distant metastasis due to breast cancer
|
after a follow up of 5 years
|
BCSS
Time Frame: after a follow up of 5 years
|
BCSS events includes death for breast cancer
|
after a follow up of 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse reaction
Time Frame: during the period of trial (up to 7 years)
|
incidence rate of Ⅲ or Ⅳ adverse reaction(according to NCI classification)
|
during the period of trial (up to 7 years)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Tao Ouyang, Doctor, Peking University Cancer Hospital Breast Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCP08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on AI+chemotherapy adjuvant therapy
-
University of JenaUniversity Hospital Erlangen; Labor Prof. PachmannRecruiting
-
Kessler FoundationUnknownBreast CancerUnited States
-
Institute of Cancer Research, United KingdomUnknownMalignant MesotheliomaUnited Kingdom
-
Beijing Stomatological HospitalBeijing Friendship Hospital; Beijing Chao Yang Hospital; The First Affiliated... and other collaboratorsRecruitingQuality of Life | Postoperative Complications | Head and Neck NeoplasmsChina
-
Sun Yat-sen UniversityUnknown
-
Shanghai Zhongshan HospitalRecruitingSurgery | Resectable Pancreatic Cancer | Adjuvant ChemoradiotherapyChina
-
Peking Union Medical College HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking... and other collaboratorsRecruitingColorectal Cancer | Colorectal Cancer Liver MetastasisChina
-
Zhejiang Cancer HospitalRecruitingGastric AdenocarcinomaChina
-
Wuhan Union Hospital, ChinaWithdrawnColorectal Cancer | Liver Metastases | RadiotherapyChina
-
Dr Kundan Singh ChufalActive, not recruitingEsophageal NeoplasmAustralia, India